New Study Raises Questions About Prostate Cancer Therapies Targeting Insulin Like Growth Factor Receptor
Therapies under development to treat prostate cancer by inhibiting the ability of insulin-like growth factor (IGF-1) to activate its target receptor could have unexpected results, especially if a major tumor suppressor gene — p53 — is already compromised, according to new research by investigators at Fred Hutchinson Cancer Research Center.
More: continued here
Filed under: Endocrinology on May 15th, 2008